| Item type |
文献 / Documents(1) |
| 公開日 |
2020-12-21 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/ehf2.12707 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1002/ehf2.12707 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure : a randomized trial (CANDLE) |
|
言語 |
en |
| 著者 |
タナカ, アツシ
ヒサウチ, イタル
タグチ, イサオ
セザイ, アキラ
トヨダ, シゲル
トミヤマ, ヒロフミ
佐田, 政隆
ウエダ, シンイチロウ
オヤマ, ジュンイチ
キタカゼ, マサフミ
ムロハラ, トヨアキ
ノデ, コウイチ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aims
Little is known about the impact of sodium glucose co‐transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes in N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), in that patient population.
Methods and results
Patients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting‐dose: 0.5 mg), were examined using the primary endpoint of non‐inferiority of canagliflozin vs. glimepiride, defined as a margin of 1.1 in the upper limit of the two‐sided 95% confidence interval (CI) for the group ratio of percentage change in NT‐proBNP at 24 weeks. Data analysis of 233 patients showed mean left ventricular ejection fraction (LVEF) at randomization was 57.6 ± 14.6%, with 71% of patients having a preserved LVEF (≥50%). Ratio of NT‐proBNP percentage change was 0.48 (95% CI, −0.13 to 1.59, P = 0.226) and therefore did not meet the prespecified non‐inferiority margin. However, NT‐proBNP levels did show a non‐significant trend lower in the canagliflozin group [adjusted group difference; −74.7 pg/mL (95% CI, −159.3 to 10.9), P = 0.087] and also in the subgroup with preserved LVEF [−58.3 (95% CI, −127.6 to 11.0, P = 0.098]).
Conclusions
This study did not meet the predefined primary endpoint of changes in NT‐proBNP levels, with 24 weeks of treatment with canagliflozin vs. glimepiride. Further research is warranted to determine whether patients with heart failure with preserved ejection fraction, regardless of diabetes status, could potentially benefit from treatment with SGLT2 inhibitors. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Type 2 diabetes |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Heart failure |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
SGLT2 inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
NT-proBNP |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Non-inferiority |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Glimepiride |
| 書誌情報 |
en : ESC Heart Failure
巻 7,
号 4,
p. 1585-1594,
発行日 2020-04-29
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20555822 |
| 出版者 |
|
|
出版者 |
The Heart Failure Association of the European Society of Cardiology |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Wiley |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| EID |
|
|
識別子 |
366094 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
ehf_7_4_1585.pdf (736 KB)
.png)
